While current economic conditions continue to restrain market growth, the U.S. market for minimally invasive bariatric surgical devices is expected to exhibit relatively good growth over the next 5 years. Valued at an estimated $147.5 million in 2010, the U.S. minimally invasive benign prostatic hyperplasia therapy systems market is expected to increase at a compound annual rate of 2.4%, with sales reaching more than $166 million in 2015. The largest segment, laser BPH therapy, is expected to drive market growth over the forecast period-expanding at a comparatively higher rate of 4.6%-at the expense of minimally invasive office-based therapies.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include transurethral microwave thermotherapy (TUMT); transurethral needle ablation (TUNA); holmium laser ablation of the prostate (HoLAP); photoselective vaporization of the prostate (PVP), or Greenlight Laser Therapy; transurethral resection of the prostate (TURP); and other energy-based technologies.
EXECUTIVE SUMMARY i. Causes ii. Symptoms iii. Diagnosis iv. Treatment a. Prescription Drugs b. Minimally Invasive Therapy c. Surgery d. Stents v. Minimally Invasive Benign Prostatic Therapy Systems Market a. Procedure Volumes Forecast b. Market Forecast vi. Methodology Exhibit ES-1: The Prostate and Urine Flow Exhibit ES-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia Exhibit ES-3: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2010-2015 Exhibit ES-4: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015 1. CLINICAL OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA 1.1 Causes 1.2 Symptoms 1.3 Diagnosis 1.4 Treatment 1.4.1 Prescription Drugs 1.4.2 Minimally Invasive Therapy 1.4.3 Surgery 1.4.4 Stents Exhibit 1-1: The Prostate and Urine Flow Exhibit 1-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia 2. MINIMALLY INVASIVE BENIGN PROSTATIC HYPERPLASIA THERAPY SYSTEMS 2.1 Transurethral Microwave Thermotherapy 2.1.1 CoreTherm: ProstaLund Operations 2.1.2 Prolieve System: Boston Scientific 2.1.3 Cooled ThermoTherapy: Urologix 2.1.4 TherMatrx Office Thermo Therapy: American Medical Systems 2.2 Transurethral Needle Ablation: Medtronic 2.3 Laser- and Other Energy-Based Therapies 2.3.1 Holmium Laser Ablation/Enucleation of the Prostate 126.96.36.199 VersaPulse PowerSuite: Lumenis 2.3.2 Photoselective Vaporization of the Prostate 188.8.131.52 GreenLight Laser Therapy: American Medical Systems 2.3.3 Other Laser-Based Technologies 184.108.40.206 EVOLVE Laser System: Biolitec 220.127.116.11 Odyssey Holmium Laser: Convergent Laser Technologies 18.104.22.168 PlasmaButton Vaporization Therapy: Gyrus ACMI/ Olympus America/Olympus 22.214.171.124 Thulium Lasers: HealthTronics/Endo Pharmaceuticals 2.3.4 Other Energy-Based Technologies 126.96.36.199 Aptocine: Light Sciences Oncology 2.4 Prostatic Stents 2.4.1 The Spanner Prostatic Stent: AbbeyMoor Medical 2.4.2 CoreFlow Soft Stent: ProstaLund Operations 2.4.3 UroLume Urethral Stent: American Medical Systems 2.5 Market Analysis 2.5.1 Procedure Volumes Forecast 2.5.2 Market Forecast 188.8.131.52 Market Drivers 184.108.40.206 Market Limiters 2.6 Competitive Analysis Exhibit 2-1: Advantages and Disadvantages of Minimally Invasive Therapy for Benign Prostatic Hyperplasia Exhibit 2-2: 2011, Selected Microwave- and Radiofrequency-Based Benign Prostatic Hyperplasia Therapy Systems Exhibit 2-3: The CoreTherm System Exhibit 2-4: Five-Year Clinical Comparison of Symptomatic Reduction in Benign Prostatic Hyperplasia Using the CoreTherm System and Competitive Treatments Exhibit 2-5: The Schelin Catheter Exhibit 2-6: The CoolWave and Targis Systems Exhibit 2-7: The Cooled ThermCath Advance Catheter Exhibit 2-8: Cooled ThermoTherapy, Selected Five-Year Clinical Trial Results Exhibit 2-9: Comparison of Cooled ThermoTherapy with Drug Therapy, Selected Clinical Results Exhibit 2-10: The Prostiva Radiofrequency Therapy System Exhibit 2-11: Holmium Laser Ablation of the Prostate Using the VersaPulse PowerSuite Laser System Exhibit 2-12: Selected Advantages of Holmium Laser Ablation Using the VersaPulse PowerSuite Compared with Photoselective Vaporization Using the GreenLight PV Exhibit 2-13: The GreenLight High Performance System Exhibit 2-14: The GreenLight Xcelerated Performance System Exhibit 2-15: The MoXy Liquid Cooled Fiber Exhibit 2-16: The EVOLVE Laser System Exhibit 2-17: PlasmaButton Vaporization Therapy Exhibit 2-18: Aptocine's Effects on Tumor Cells, and Selected Benefits of Aptocine Treatment Exhibit 2-19: The Spanner Prostatic Stent Exhibit 2-20: The CoreFlow Soft Stent Exhibit 2-21: Benefits of the UroLume Urethral Stent Exhibit 2-22: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy,Procedure Volumes Forecast, 2010-2015 Exhibit 2-23: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015 Exhibit 2-24: 2010, Benign Prostatic Hyperplasia Laser Therapy Systems Market, Share by Supplier Exhibit 2-25: 2010, Transurethral Microwave Thermotherapy and Transurethral Needle Ablation Systems Market, Share by Supplier 3. COMPANY PROFILES 3.1 American Medical Systems, Inc. 3.2 Boston Scientific Corporation 3.3 Lumenis LTD 3.4 Medtronic, Inc. 3.5 Olympus America/Olympus Corporation 3.6 ProstaLund Operations AB 3.7 Urologix, Inc. APPENDIX: COMPANY LISTING